Wyatt is a seasoned life sciences executive and strategy consulting leader experienced in asset and franchise growth strategy and mergers and acquisitions/transaction advisory support. He currently leads the Evidence, Value and Access business for Cytel, and was previously Sr. VP for the Market Access and Health Economics business for global CRO Parexel, and Partner for Parexel consulting subsidiary Health Advances. Prior to this, Wyatt was with Boston Consulting Group (BCG) and the head of New Product Commercialization for Biogen. He has led domestic and global teams in marketing strategy, portfolio management, new product commercialization, and market access. He offers expertise in strategy development, life cycle management, valuation, diligence, and digital health, and has advised or supported the integration of >$40B in life sciences transactions. Wyatt also serves as independent Board member of Diceros Therapeutics.